Dupilumab for immune checkpoint inhibitors‐induced pruritic dermatoses: A retrospective, multicentric study
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Authors
- Konstantinos Lallas (ORCID: https://orcid.org/0000-0001-9306-7295)
- Chrysa Oikonomou
- Azael Freites‐Martínez (ORCID: https://orcid.org/0000-0002-3121-5667)
- Vasiliki A. Nikolaou (ORCID: https://orcid.org/0000-0001-9340-9152)
- Priscila Giavedoni (ORCID: https://orcid.org/0000-0002-1474-9261)
- Florentina Delli (ORCID: https://orcid.org/0000-0002-2344-7118)
- Lukas Kraehenbuehl (ORCID: https://orcid.org/0000-0001-5411-5661)
- Célèste Lebbé (ORCID: https://orcid.org/0000-0002-5854-7290)
- Dimitra Koumaki (ORCID: https://orcid.org/0000-0001-7074-2374)
- Thierry Passeron (ORCID: https://orcid.org/0000-0002-0797-6570)
- Cristina Carrera (ORCID: https://orcid.org/0000-0003-1608-8820)
- Ana Clara Torre (ORCID: https://orcid.org/0000-0001-9670-6566)
- Pietro Sollena (ORCID: https://orcid.org/0000-0002-1632-7791)
- Davide Fattore (ORCID: https://orcid.org/0000-0002-1925-1243)
- Yannick S. Elshot (ORCID: https://orcid.org/0000-0001-7148-2439)
- Francesca Bruni (ORCID: https://orcid.org/0000-0001-7248-425X)
- Damien Giacchero
- Julia Riganti (ORCID: https://orcid.org/0000-0001-5382-1863)
- Alicia Jiménez Antón (ORCID: https://orcid.org/0000-0002-0623-8744)
- Jesse Hirner
- E. Gérard (ORCID: https://orcid.org/0000-0003-1765-461X)
- Olivier Gaide (ORCID: https://orcid.org/0000-0002-2865-7595)
- V. Sibaud (ORCID: https://orcid.org/0000-0003-2585-6633)
- Zoé Apalla (ORCID: https://orcid.org/0000-0002-9255-8196)
- Michela Valeria Rita Starace (ORCID: https://orcid.org/0000-0002-3981-1527)
- Emma Huard
- Johana Rousset
Institutions
- Inserm (FR)
- National and Kapodistrian University of Athens (GR)
- University of Zurich (CH)
- Université Paris Cité (FR)
- Aristotle University of Thessaloniki (GR)
- Dutch Cancer Society (NL)
- University of Missouri Health System (US)
- General University Hospital of Patras (GR)
- Saint Louis University Hospital (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Hospital Italiano de Buenos Aires (AR)
- Agostino Gemelli University Polyclinic (IT)
- The Netherlands Cancer Institute (NL)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- University Hospital of Zurich (CH)
- Oncode Institute (NL)
- Hospital Clínic de Barcelona (ES)
- Hôpital Orthopédique de la Suisse Romande (CH)
- Ippokrateio General Hospital of Thessaloniki (GR)
- Centre Méditerranéen de Médecine Moléculaire (FR)
- Azienda USL di Bologna (IT)
- Institut de Recherche sur le Cancer et le Vieillissement de Nice (FR)
- University Hospital of Heraklion (GR)
- Hôpital Pasteur (FR)
- Hôpital Saint-Louis (FR)
- Hospital Universitario Puerta del Mar (ES)
- Amsterdam University Medical Centers (NL)
- University of Naples Federico II (IT)
- University of Amsterdam (NL)
- Universidad Europea de Madrid (ES)
- University of Bologna (IT)
- University of Lausanne (CH)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1111/jdv.70122
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09